Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 337       
ORIGINAL ARTICLE
Year : 2016  |  Volume : 143  |  Issue : 7  |  Page : 104-111

Microsatellite instability & survival in patients with stage II/III colorectal carcinoma


1 Center for Gastroenterology and Hepatology, Zvezdara University Clinical Center; School of Medicine, University of Belgrade, Belgrade, Serbia
2 Genetic Laboratory, Institute for Endocrinology, Clinical Center of Serbia, Belgrade, Serbia
3 Center for Colorectal Surgery, Clinical Center of Serbia, Belgrade, Serbia
4 School of Medicine, University of Western Sydney, Campbelltown; New South Wales, Australia
5 Center for Colorectal Surgery, Clinical Center of Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia
6 Genetic Laboratory, Institute for Endocrinology, Clinical Center of Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia

Correspondence Address:
Markovic Srdjan
Dimitrija Tucovica 161, 11000, Belgrade
Serbia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-5916.191801

Rights and Permissions

Background & objectives: The two key aspects associated with the microsatellite instability (MSI) as genetic phenomenon in colorectal cancer (CRC) are better survival prognosis, and the varying response to 5-fluorouracil (5-FU)-based chemotherapy. This study was undertaken to measure the survival of surgically treated patients with stages II and III CRC based on the MSI status, the postoperative 5-FU treatment as well as clinical and histological data. Methods: A total of 125 consecutive patients with stages II and III (American Joint Committee on Cancer, AJCC staging) primary CRCs, were followed prospectively for a median time of 31 months (January 2006 to December 2009). All patients were assessed, operated and clinically followed. Tumour samples were obtained for cytopathological verification and MSI grading. Results: Of the 125 patients, 21 (20%) had high MSI (MSI-H), and 101 patients (80%) had MSI-L or MSS (low frequency MSI or stable MSI). Patients with MSS CRC were more likely to have recurrent disease (P=0.03; OR=3.2; CI 95% 1-10.2) compared to those with MSI-H CRC. Multi- and univariate Cox regression analysis failed to show a difference between MSI-H and MSS groups with respect to disease-free, disease-specific and overall survival. However, the disease-free survival was significantly lower in patients with MSI-H CRC treated by adjuvant 5-FU therapy (P=0.03). Interpretation & conclusions: MSI-H CRCs had a lower recurrence rate, but the prognosis was worse following adjuvant 5-FU therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed747    
    Printed10    
    Emailed0    
    PDF Downloaded233    
    Comments [Add]    
    Cited by others 1    

Recommend this journal